Schedule 13G ownership disclosure

CytomX Therapeutics Inc

Common Stock, par value $0.00001 per share · CUSIP: 23284F105

Event date: 2025-12-31

Filing-level shares
3,525,650.00
Percent of class
2.1%
  • OrbiMed Advisors LLC

    Shares: 3,525,650.00 · Class: 2.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000947871-26-000190
Form type
SCHEDULE 13G/A
Filer
CytomX Therapeutics, Inc.
CIK
CIK 1501989
Filed
Feb 17, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub